Wright Laura E, Guise Theresa A
Authors' Affiliations: Department of Medicine, Division of Endocrinology, Indiana University School of Medicine; and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
Authors' Affiliations: Department of Medicine, Division of Endocrinology, Indiana University School of Medicine; and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IndianaAuthors' Affiliations: Department of Medicine, Division of Endocrinology, Indiana University School of Medicine; and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Clin Cancer Res. 2014 Jun 1;20(11):2817-9. doi: 10.1158/1078-0432.CCR-14-0576. Epub 2014 May 6.
Factors released during osteoclastic bone resorption enhance disseminated breast cancer cell progression by stimulating invasiveness, growth, and a bone-resorptive phenotype in cancer cells. Postmenopausal bone loss may accelerate progression of breast cancer growth in bone, explaining the anticancer benefit of the bone-specific antiresorptive agent zoledronic acid in the postmenopausal setting. Clin Cancer Res; 20(11); 2817-9. ©2014 AACR.
破骨细胞骨吸收过程中释放的因子通过刺激癌细胞的侵袭性、生长和骨吸收表型，促进播散性乳腺癌细胞的进展。绝经后骨质流失可能加速乳腺癌在骨中的生长进程，这解释了骨特异性抗吸收药物唑来膦酸在绝经后环境中的抗癌益处。《临床癌症研究》；20(11)；2817 - 2819。©2014美国癌症研究协会。
